ArticleFrontiers in oncology2025
Case Report: Esophageal malignant melanoma with lung adenocarcinoma: a rare case of dual primary cancers.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary melanoma of the gastrointestinal tract.World journal of gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary malignant melanoma of the esophagus (PMME) is a rare type of gastrointestinal melanoma characterized by its aggressive nature and poor prognosis, with a 5-year survival rate of less than 5%. This study reports a case of a male patient with PMME complicated by primary lung adenocarcinoma. The main symptom of the patient was progressive dysphagia. Endoscopically, a polypoid mass was observed protruding into the lumen of the lower esophagus, with melanin pigmentation on the tumor surface, part of which was smooth and part showed ulceration. Enhanced chest and abdominal CT, as well as PET-CT, were consistent with esophageal malignancy, the left lung was consistent with lung cancer, and the right was considered metastatic. CT-guided percutaneous lung biopsy and immunohistochemistry indicated left lung invasive adenocarcinoma. PMME is extremely rare, and the co-occurrence of lung adenocarcinoma as a double primary cancer is even rarer in clinical practice. The disease has a high degree of malignancy and poor prognosis, with diagnosis mainly relying on endoscopic examination, pathological histological morphology, and immunohistochemistry. Early detection and diagnosis are currently key to treating this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.